Diethylcarbamazine Citrate

Filariasis is one of the oldest, most dangerous, debilitating, disfiguring diseases and often ignores tropical disorders. It presents with a range of clinical symptoms, a low death rate, and a high morbidity rate, which contributes to social discrimination. This condition has major effects on people's socioeconomic circumstances. This illness is carried by mosquitoes that have spread malaria. Lymphatic filariasis, caused by Wuchereria bancrofti, Brugia malayi, and Brugia timori, is a crippling illness with serious social and economic consequences. The infection persisted despite therapy with conventional antifilarial medications such as diethylcarbamazine (DEC), albendazole, and ivermectin, which are mostly microfilaricides. Current treatments (ivermectin, diethylcarbamazine, and albendazole) have limited effectiveness against adult parasites and produce side effects; therefore, innovative antifilarial medications are urgently required. Hence, macrofilaricides, embryostatic agents, and improved microfilaricides are required. The following article discusses the typical synthetic methodologies established for antifilarial activity as well as their marketed pharmaceuticals, which will help researchers, medicinal chemists, and pharmaceutical scientists to develop new and effective antifilarial therapies. This review can help to identify new lead compounds and optimize existing commercial medications to improve their therapeutic efficacy. The majority of the studies addressed in this review concern the forms of filariasis, parasite life cycle, symptoms, medications used to treat filariasis, synthetic schemes, SAR, and results from the reported research.

Mass Drug Administration (MDA) of Di-Ethyl Carbamazine and Albendazole is an effective strategy recommended by the World Health Organization to prevent transmission and eliminate lymphatic filariasis. Under the National Vector Borne Disease Control Programme (NVBDCP) in India, MDA is carried out as a yearly activity in endemic areas to accelerate the progress towards elimination of lymphatic filariasis. The study was carried with the objective to determine the coverage of MDA against lymphatic filariasis among the eligible population in Kalaburagi district, Karnataka and delineate the common reasons for non-acceptance of MDA.

Field-based cross-sectional survey was carried out. Cluster sampling of 4 clusters (3 rural and 1 urban) from four different taluks (one cluster from each taluk) of the district reporting high, medium and low coverage of MDA (as reported by District Malaria Office) Members from selected households in all clusters were interviewed regarding MDA administration, directly observed treatment, side effects and any co morbidities which ruled out MDA administration. Responses documented as tally marks in assessment sheets shared by NVBDCP office. Proportions, frequencies, and mean were calculated and inferential statistics were used.

A total of 1263 individuals were assessed for MDA from a total 240 households (60 households in each cluster). The coverage of MDA varied from 90.33% in Heerapur in Kalaburagi Urban to 97.87% in Mogala thanda (Chittapur Taluk).

MDA Coverage against lymphatic filariasis has improved when compared to previous studies and it has also exceeded the coverage threshold as determined by programme for elimination of lymphatic filariasis.